Navigation Links
Cutting-edge approaches to ensuring biologic drug quality focus of forum on bioassays

Rockville, Md., November 16, 2012 As a growing number of biologic drugs are treatments of choice for an expanding list of autoimmune disorders, inflammatory diseases, and certain cancers, bioassays play a critical role in establishing the functional integrity and potency of these products. Hosted by the United States Pharmacopeial Convention (USP), the Fifth Bioassay Workshop will take place on December 4-5, 2012, at USP's headquarters in Rockville, Md. The workshop will focus on the development, monitoring and validation/revalidation of bioassays. It will feature perspectives from manufacturers, regulators and other stakeholders on such topics as the replacement of animal-based assays with cell-based assays; USP's standards for bioassays; software selection for bioassay development and other related topics.

According to Roger L. Williams, M.D., chief executive officer of USP, "Developing standards for modern medicines such as biologics is a complicated yet important undertaking. Through forums like USP's Fifth Bioassay Workshop, manufacturers, regulators and other stakeholders can exchange ideas and strategies for approaching important issues such as bioassay development. Being able to share information and expertise undergirds our ability to create standards that help to ensure the quality of the global drug supply."

Conventional pharmaceuticals are made through chemical routes and have small molecular structures. Biologicsparticularly more modern ones such as recombinant proteins and monoclonal antibodiesare larger and more complex in their makeup, and are derived from living cells or organisms. As a result, it is not possible to fully characterize biologic drugs in the same way that chemical drugs are characterized using commonly-applied analytical techniques and procedures. Bioassays are used to assign or confirm drug potency and to validate that a drug is functioning as expected, usually by comparison to a known reference standard. Since manufacturing processes for biologics are continuously changing throughout the development and life cycle of a biologic drug, bioassays are important for maintaining the integrity of a drug's potency and for determining that the drug is continuing to work in the manner in which it is intended.

Cell-based assays will be one of the topics discussed at the USP Bioassay Workshop. USP's current activities in this area include standards development for biological medicines involving cell-based assays to measure erythropoietin bioactivity and somatropin cell-based bioidentity methods. Emerging technologies are making it possible for manufacturers to consider novel methods for measuring a drug's potency. Compared to traditional animal-based testing, some newer cell-based assays are enabling more precise measurements of potency and drug activity and are proving to be easier to execute in the laboratory. However, manufacturers must be able to demonstrate that newer, cell-based assays are suitable replacements for older methods based on clinical and safety data obtained using previous assays and clinical trial batches of the drug. Regulatory perspectives on the implementation of new methods will also be discussed.

In August 2012, a suite of standards known as the "USP Bioassay Chapters" became official in USP's published compendia of standardsUnited States Pharmacopeia and the National Formulary (USPNF). The December workshop will feature a session dedicated to the USP Bioassay Chapters and will include presentations on user feedback regarding their applicability to bioassay development and validation during drug development and post-licensure stages. Perspectives on bioassay challenges from the U.S. Food and Drug Administration (FDA) also will be featured during this session.

While great emphasis is placed on validation and use of bioassay methods, the qualification of critical reagents and references materials used during the life cycle of a product also is very important. Strategies for monitoring and replacing these materials will be highlighted during the workshop.

The workshop also will provide attendees with a unique opportunity to interact with vendors of bioassay development software. In addition to an open-forum Q&A session with software vendors, one-on-one discussion sessions with vendors will allow users to elaborate on their own in-house needs and determine how specific software offerings can address them.

Registration is available at a rate of $950 for industry and $500 for association/government/academia. Group discounts are also available. For information on USP's Pharmacopeial Education course on USP's Bioassay Chapters on December 3, 2012, click here. For information about the workshop, go to: Hear from one of USP's Expert Committee members about the workshop by clicking


Contact: Theresa Laranang-Mutlu
US Pharmacopeia

Related medicine news :

1. More cutting-edge cancer research supported by industry
2. AGA presents cutting-edge research during DDW®
3. ASHA grant funds cutting-edge AIDS research at Tel Aviv University
4. New national clinical trials network for neurological disorders to foster cutting-edge treatments
5. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
6. GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
7. NIH awards $7.8 million for innovative HIV vaccine approaches
8. As painkiller overdoses mount, researchers outline effective approaches to curb epidemic
9. Control of disease activity and biologic treatment increase life expectency in RA patients
10. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
11. Study Compares Safety of Biologic Meds for Rheumatoid Arthritis
Post Your Comments:
(Date:12/1/2015)... ... ... The Multiple System Atrophy Coalition has announced the launch of its MSA Can’t ... today to coincide with Giving Tuesday 2015, a global day of fundraising. , ... be productive, to do simple daily activities like walking to the mailbox and eating ...
(Date:12/1/2015)... ... December 01, 2015 , ... Royal River Natural Foods — a locally-owned, ... post-menopausal women who took the nutritional supplement creatine, along with resistance training for a ... not take creatine. , The report is part of the December 2015 issue of ...
(Date:12/1/2015)... ... 2015 , ... Baptist Medical Center Jacksonville has implanted the ... hospital in the region providing what is known as the world’s smallest pacemaker. ... revealed recently at a medical conference and published in The New England Journal ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... to continue the expansion of the company’s growing product line of food safety ... (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015  Eyeon Therapeutics has received a ... treatments based on a charged hydrophilic polymer developed ... The product has been shown to be safe ... Mark Mitchnick , MD, CEO states, "This ... additional polymers in conjunction with a therapeutic agent.  ...
(Date:12/1/2015)... 1, 2015  Athletic apparel company Tommie ... to pay $1.35 million to settle Federal Trade ... copper-infused compression clothing would relieve severe and chronic ... diseases. Tommie Copper,s proposed ... and its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... diciembre de 2015  AccuTEC Blades, una ... precisión, develó hoy un nuevo logo corporativo ... El nuevo logo destaca la experiencia de ... de productos con cuchillas donde "el borde ... --> ...
Breaking Medicine Technology: